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Abstract: A recent study demonstrated the lack of beta-amyloid (Aβ) plaque formation and accumulation of the 
amyloid precursor protein (APP) in a triple transgenic mouse model of Alzheimer’s disease (3xTg-AD) following 
overexpression of the anti-apoptotic protein, Bcl-2 (Rohn et al., J. Neurosci. 28: 3051-9, 2008). The supposition 
from that study was the accumulation of APP resulted from a decrease in caspase-mediated processing of APP.  
To determine a direct role for the caspase-cleavage of APP in 3xTg-AD mice, we designed a site-directed caspase-
cleavage antibody to APP and demonstrated it is a specific marker for caspase-cleaved APP. Application of this 
antibody revealed neuronal staining in the hippocampus and subiculum of 3xTg-AD mice.  These results were 
confirmed utilizing a similar site-directed antibody to caspase-cleaved APP (APPneo).  The caspase cleavage of 
APP as well as the formation of extracellular Aβ plaques was prevented in 3xTg-AD animals overexpressing Bcl-2.  
These results provide further support that caspases play a proximal role in promoting the pathology associated 
with AD. 
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Introduction 
 
In Alzheimer’s disease, Aβ deposition is 
accompanied by the gradual replacement of 
the neuronal cytoskeleton with insoluble NFTs.  
NFTs are intracellular fibrillary inclusions 
composed of aggregations of paired helical 
filaments (PHFs), which are made up of 
abnormally phosphorylated and truncated tau 
[1].  According to the Aβ hypothesis, Aβ 
precedes NFT formation, suggesting that Aβ 
may be the earliest event that triggers 
downstream events [2].   Several studies have 
supported the hypothesis that Aβ formation 
and NFT formation may be closely linked 
through a common pathway of caspase-
mediated proteolysis [3-5].  Direct evidence 
supporting a role for caspases in promoting 
the pathology associated with AD come from 
several transgenic mouse studies: Galvan et 
al. demonstrated that deleting the C-terminal 
caspase-cleavage consensus site within APP 
reversed the pathology and behavioral deficits 
associated with human APP transgenic mice 
[6].  In a recent study by Spires-Jones et al., 
the authors used in vivo imaging in rTg4510 
mice, a reversible mouse model of tauopathy, 
to demonstrate the activation of caspases 
within tangle-bearing neurons [7].  Finally, we 
have developed a triple-transgenic mouse 
model (3xTg-AD) that overexpress the anti-
apoptotic protein, Bcl-2, in all postmitotic 
neurons of the CNS.  Overexpression of Bcl-2 
prevented caspase activation, the caspase 
cleavage of tau and improved place 
recognition memory in 3xTg-AD mice [8].  An 
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additional finding of that study was the 
accumulation of full-length APP and tau 
following overexpression of Bcl-2 in 3xTg-AD 
mice [8].  The interpretation of this finding was 
the observed accumulation of APP and tau 
resulted from an inhibition in caspase-
mediated proteolysis following overexpression 
of Bcl-2.    However, direct demonstration that 
APP is cleaved by caspases and is prevented 
following overexpression of Bcl-2 was not 
investigated.  The goal of the present study 
was examine directly a role for caspase-
mediated cleavage of APP in 3xTg-AD mice 
utilizing a novel site-directed caspase-cleavage 
antibody to APP.  Following application of this 
antibody and a similar antibody developed by 
Galvan et al. [6], we now demonstrate 
caspase-cleavage of APP does occur in 3xTg-
AD mice and is prevented along with the 
formation of extracellular deposits of Aβ 
following overexpression of Bcl-2. These 
results provide further support for a role of 
caspases in the disease progression 
associated with AD. 
 
Methods and Materials   
 
Animals  
 
The generation and characterization of 3xTg-
AD mice that overexpress the anti-apoptotic 
protein, Bcl-2, have been described previously 
[8].  In brief, 3xTg-AD mice harbor three known 
mutations, human APPSwe, human tauP301L and 
PS1M146V known to give rise to the heritable 
forms of AD [9].  These mice, termed 3xTg-AD 
mice, progressively develop plaques and 
tangles in a manner that closely recapitulates 
the disease process in the human AD brain 
[9]. To generate 3xTg-AD mice that 
overexpress the anti-apoptotic protein, Bcl-2, 
3xTg-AD mice were crossed with Tg mice that 
overexpress the human Bcl-2 gene in all post-
mitotic neurons [10]. The progeny resulting 
from such a cross have been termed 3xTg-
AD/Bcl-2 overexpressors (3xTg-AD/Bcl-2 OE). 
Littermates that were negative for the human 
Bcl-2 gene were used for comparison.  
 
Tissue acquisition   
 
Mice were anesthetized with pentobarbital, 
perfused with saline, and the brains rapidly 
removed.  Brains were divided into 
hemispheres and one hemisphere was sunk in 
4% phosphate-buffered paraformaldehyde, 
while the other hemisphere was snap frozen at 
–50°C in isopentane.  Mouse brains were 
mounted coronally and sectioned serially at 50 
µm on a vibratome, and stored for 
immunohistochemistry. 
 
Generation of a caspase-cleavage, site-
directed antibody to the amyloid precursor 
protein  
 
Previous studies have demonstrated the 
caspase-3 cleavage of the 120 kDa peptide of 
APP results in two small fragments (23 and 25 
kDa); both of these sites are within the first 
220 amino acids while a third cleavage site at 
aspartic residue 739, creates a larger 
polypeptide (~85 kDa) [11].  A polyclonal 
antibody, herein termed APP caspase-cleavage 
product (ccp) was synthesized based upon a 
putative caspase-3 cleavage site (VEVD739) 
within APP [11].  A 7-mer peptide (HGVVEVD) 
corresponding to the upstream neoepitope 
fragment, that would be generated following 
cleavage, was coupled to a cysteine group to 
facilitate the conjugation of the adjuvant, KLH.  
The resulting peptide ([KLH] - CHGVVEVD) was 
injected into rabbits and the resulting sera was 
used to affinity purify antibodies using a 
sulfolink column coupled with the peptide 
(CHGVVEVD). Synthesis of peptides, injections 
of immunogens, and collection of serum was 
completed by Bethyl laboratories 
(Montgomery, TX).  
 
Antibody dilutions 
 
Primary antibodies used in immunohisto-
chemical analysis were diluted as follows: 
APPccp, 1:100-150; mAB 1560 anti-A (clone 
6e10, Chemicon, Temecula, CA), 1:400; 
APPneo, 1:1000; and Tau C3 (Chemicon, 
Temecula, CA), 1:100.     
 
Cerebral ischemia produced by middle 
cerebral artery occlusion, a model of apoptosis 
 
Brain sections were generously provided to us 
by Dr. Sheng T. Hou (Experimental 
NeuroTherapeutics Laboratory, National 
Research Council Institute for Biological 
Sciences, National Research Council Canada, 
Ottawa, Ontario, Canada). C57BL/6 mice (20-
23 g) were subjected to middle cerebral artery 
occlusion (MCAO) as described previously [12].  
Briefly, under anesthesia, mice were subjected 
to MCAO using an intraluminal filament for 1 
hr. After 1 hr of MCAO, the filament was 
removed and blood flow was restored for 24 hr 
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at which time animals were sacrificed.  Mouse 
brains were perfused with 10% formalin in 
PBS, then post-fixed in 10% formalin for 4 hr 
and cryo-protected overnight in phosphate 
buffer containing 30% sucrose at 4°C.  
Following fixation, brains were sectioned into 
50 µm free-floating sections to be processed 
by immunohistochemistry.  Apoptotic areas 
were identified by Hoechst staining as 
described previously [12].   
 
Fluoro Jade C labeling 
 
To assess for neurodegeneration and 
apoptosis, the fluorescent dye, Fluoro Jade C 
(Millipore, catalog number AG325) was utilized 
as previously described by Bian et al. [13]. 
Briefly, fixed brain sections were mounted and 
pretreated for 5 min in a 80% alcohol solution 
containing 1% sodium hydroxide, followed by a 
70% alcohol and a distilled water wash for 2 
min.  Sections were then incubated for 10 min 
in a 0.06% potassium permanganate solution 
followed by rinsing in distilled water for 2 min.  
Sections were then transferred into a 
0.0001% solution of Fluoro Jade C containing 
0.1% acetic acid for 10 min.  Following 3 
successive washes in distilled water for 1 min, 
slides were dried, dehydrated and cover-
slipped with Depex. 
 
Cell-free digestion of APP 
 
To examine whether caspase-3 can cleave 
APP, 1 µg of purified human recombinant APP 
(Calbiochem) was incubated with active 
human recombinant caspase-3 (Calbiochem) 
in 2x reaction buffer containing 10 mM DTT for 
two hours at 37°C.  Reactions were 
terminated by the addition of 5x sample buffer 
and stored at -20°C until analyzed. 
 
ELISA 
 
Antibody titers were determined with an 
enzyme-linked immunoassay (ELISA).  Samples 
were run in triplicate on ELISA plates coated 
with the peptide, CHGVVEVD, which was used 
as the immunogen.  The peptide CHGVVEVD 
was bound in solid phase on high binding 96 
well plates (Dynex Technologies).  Serum was 
diluted 1:500 and then serially diluted to a 
final dilution of 1:64,000. Detection of the 
antibody was obtained using an HRP 
conjugated secondary antibody (1:5,000) and 
TMB micro well peroxidase substrate (KPL 
Protein Research Products). 
 
Human Subjects 
 
Autopsy brain tissue from the hippocampus 
and entorhinal cortex of five neuropatho-
logically confirmed AD cases and five 
nondemented cases diagnosed as normal was 
studied. Human brain tissues used in this 
study were provided by the Institute for Brain 
Aging and Dementia Tissue Repositories at the 
University of California, Irvine. 
Figure 1.  Characterization of the APPccp antibody 
in vitro.  (A): ELISA results utilizing preimmune 
(circles) or immunized (squares) sera indicated a 
high titer of antibody following immunization of 
rabbits with the peptide, [KLH]-CHGVVEVD.  Results 
are representative of three separate experiments 
ran in triplicate, ±S.E.M.  (B) Recombinant human 
APP was incubated in the presence or absence of 
caspase-3 for 2 hours at 37°C.  Samples were 
separated by SDS-PAGE and gels were stained with 
coomassie blue (left panel) or transferred to 
nitrocellulose and probed with affinity-purified 
APPccp antibody (1:500).  Incubation of full-length 
APP with caspase-3 led to efficient processing and 
formation of two prominent fragments (65 and 25 
kDa, left panel). Western blot analysis indicated 
that the APPccp antibody recognizes only the 
caspase-cleaved fragment (~25 kDa) fragment and 
does not detect full length APP (~100 kDa). 
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Immunohistochemistry and 
immunofluorescence 
 
Free-floating 50 µm-thick serial sections were 
used for immunohistochemical and 
immunofluorescence studies conducted as 
previously described by Mouser et al., [14]. 
Antigen visualization was determined using 
ABC complex (ABC Elite immunoperoxidase kit, 
Vector labs), followed by DAB substrate (brown 
product) or with nickel chloride, which 
generates a black product or NovaRed, which 
generates an orange product (Vector Labs). 
MCAO brain sections were labeled with APPccp 
antibody (1:100) followed by streptavidin Alexa 
Fluor 555 (red, Ex/Em = 555/565).  To 
visualize nuclei, sections were also incubated 
in Hoechst. 
 
Western blot analysis  
 
Full-length APP, or APP digested with caspase-
3 were stored in 5x sample buffer at -20°C 
until analyzed.  Samples were boiled for 5 
minutes, placed on ice then loaded onto 12% 
SDS-PAGE gels. Gels were either stained with 
coomassie blue to detect total protein content, 
or slabs were transferred to nitrocellulose for 
Western blot analysis.  Western blot analysis 
was performed utilizing the One-StepTM 
Advanced Western rabbit kit according to 
manufacturer’s directions (GenScript 
Corporation, Piscataway, NJ). Samples were 
analyzed for protein content using the BCA 
assay (Pierce) to ensure equal protein loading. 
 
Results 
 
Characterization of a site-directed caspase-
cleavage antibody to APP 
 
To examine whether APP is a target for 
caspase cleavage in 3xTg-AD mice, we 
synthesized a site-directed antibody according 
to a putative caspase cleavage site (VEVD739) 
located at the C-terminal end of APP. The 
antibody was directed towards the upstream 
neo-fragment that would be generated 
following cleavage by caspase-3 at this site. 
Cleavage of APP by caspase-3 at this 
consensus site results in a predicted fragment 
of 25 kDa [11].  An 8-mer peptide was 
conjugated to KLH ([KLH]-CHGVVEVD) and 
injected into rabbits.  As shown in Figure 1A, a 
strong antibody titer was obtained following 
immunization of rabbits with this peptide as 
compared to preimmune serum.  Following 
affinity purification, we tested the specificity of 
this antibody (herein termed the APP caspase-
cleavage product (ccp) antibody) utilizing a 
cell-free system consisting of purified human 
recombinant APP incubated with or without 
caspase-3.  Following digestion of APP, 
samples were separated by SDS-PAGE gel 
electrophoresis and either stained with 
coomassie blue (left panel, Figure 1B) or 
transferred to nitrocellulose and probed with 
the APPccp antibody (right panel, Figure 1B).  
While no immunoreactivity was evident in non-
digested samples, a prominent band was 
visible at 25 kDa, corresponding to the 25 kDa 
fragment generated following digestion of APP 
with caspase-3 (Figure 1B, right panel).   These 
results indicate the APPccp antibody 
recognizes only the caspase-cleaved fragment 
(~25 kDa) and does not detect full length APP 
(~100 kDa).     
 
Experiments were performed to further 
characterize the APPccp antibody in an in vivo 
model system of ischemia, which has 
Figure 2. Detection of caspase-cleaved APP in an 
animal model of apoptosis. Mice were subjected to 
1 hr MCAO, followed by reperfusion for 24 hr.  (A 
and B): Brain sections incubated with Fluoro Jade 
C revealed labeling of shrunken, damaged neurons 
in the cortex of MCAO mice in ischemic infarct 
areas (A), while no staining with Fluoro Jade C was 
evident on the contralateral control side of the 
brain (B). (C and D): Identical to Panels A and B 
except sections were analyzed for caspase-cleaved 
APP using the APPccp antibody.  In this case, 
APPccp staining (red) was evident in ischemic 
infarct areas (C) and was largely absent on the 
contralateral side of the brain (D).  Nuclei were 
identified following staining with Hoechst (Blue). 
Scale bars represent 10µm. 
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previously been shown to activate apoptotic 
pathways [12].  The advantage of this model is 
that it creates an ischemic infarct confined to 
one side of the brain while leaving the other 
hemisphere undamaged, which thus can serve 
as an internal control.  As an initial approach, 
we first determined whether we could detect 
neurodegeneration in ischemic infarct regions 
of MCAO mice.  To accomplish this, we 
employed the use of a specific marker for 
neurodegeneration, Fluoro Jade C.  Fluoro 
Jade C is a fluorescent dye that detects 
neuronal degeneration in animal models and 
displays a high degree of specificity and 
sensitivity [13]. Application of Fluoro Jade C to 
MCAO brain sections revealed widespread 
neuronal labeling in ischemic infarct areas 
(Figure 2A), while the contralateral side of the 
brain showed no evidence of labeling (Figure 
2B).  These data suggest that activation of 
apoptotic pathways and neurodegeneration 
does indeed occur in MCAO mice.  Sections 
were further analyzed for caspase-cleaved APP 
using APPccp and revealed the labeling of 
neurons in ischemic infarct areas.  For these 
experiments, sections were also incubated 
with the nuclear label, Hoechst (shown in blue, 
Figure 2C) to indicate whether nuclei were 
condensed or fragmented, a characteristic 
morphological feature of apoptosis. In this 
regard, we found co-localization of APPccp 
within neurons that were clearly displaying 
nuclear condensation and fragmentation 
(Figure 2C).  In contrast there was no labeling 
of the APPccp antibody on the contralateral 
side of the brain and the nuclei appeared 
normal (Figure 2D). These data provide further 
support that the APPccp antibody is a specific 
probe for caspase-cleaved APP.   
 
Following confirmation that the APPccp 
antibody is specific for the C-terminal caspase-
cleavage fragment of APP, immunohisto-
chemical analysis was performed using human 
postmortem hippocampal sections from AD 
and age-matched control brains. A previous 
study has shown that APP is cleaved by 
caspase-3 predominantly within the 
cytoplasmic tail of APP, a cleavage event, 
which also occurs in the human AD brain [11, 
15].  In age-matched control sections, little 
labeling was observed following application of 
the APPccp antibody (Figure 3A).  In contrast, 
labeling of APPccp was evident within 
hippocampal neurons, and within plaque-rich 
regions in cases exhibiting pathology 
consistent with AD (Figure 3B and C).  Taken 
together (Figs. 1-3), these findings validate the 
APPccp as a specific probe to detect caspase-
cleaved APP. 
 
Detection of caspase-cleaved APP in 3xTg-AD 
and its prevention following overexpression of 
Bcl-2 
 
To test whether the caspase-cleavage of APP 
occurs in 3xTg-AD mice, brain sections of 18 
and 24 month-old mice were analyzed by 
immunohistochemistry.  Little labeling was 
observed in age-matched nonTg control mice 
(data not shown).  Strong neuronal labeling 
was evident primarily within the subiculum in 
both 18 and 24 month-old 3xTg-AD mice 
(Figure 4A and C).  Interesting, the APPccp 
Figure 3. Characterization of APPccp antibody in the human AD brain by immunohistochemistry.  Data are 
representative staining from human postmortem hippocampal brain sections following application of the 
APPccp antibody. (A): Representative age-matched control section following labeling with APPccp indicating a 
general lack of staining. (B and C): Labeling of APPccp in a representative AD case was evident within 
hippocampal neurons with apparent NFT morphology (arrow, B) and within plaque-rich regions (arrows, C). 
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antibody did not immuno-detect A plaques, 
suggesting that the C-terminal cleavage 
fragment of APP is not extracellularly 
deposited.  In contrast to 3xTg-AD mice, there 
was no staining following application of the 
APPccp antibody in 3xTg-AD mice 
overexpressing the antiapoptotic protein, Bcl-2 
(Figure 4B and D).  To confirm these findings, 
we employed the use of a similar site-directed 
caspase-cleavage antibody to APP developed 
by Galvan et al. [6, 16].  This antibody, termed 
APPneo, selectively recognizes the neo-C-
terminus fragment of APP generated by 
caspase-mediated cleavage of APP [16].  
Application of APPneo in 3xTg-AD mice 
revealed labeling within neuronal cell bodies 
and dystrophic neurites in hippocampal and 
cortical regions (Figure 5A and C), which was 
absent in 3xTg-AD mice overexpressing Bcl-2 
(Figure 5B and D).   
 
In a previous study, overexpression of Bcl-2 in 
3xTg-AD mice prevented the caspase cleavage 
of tau, the formation of extracellular plaques, 
and led to an accumulation of both APP and 
tau [8].  To extend these findings, we 
performed double-label immunohistochemical 
experiments using the APPccp antibody 
together with anti-Aβ 1560 (clone 6E10), an 
antibody known to react with both the A 
peptide as well as with full-length APP [17].  
Strong staining of plaques with little neuronal 
staining was observed following application of 
the Aβ 1560 antibody in 3xTg-AD mice (brown 
labeling, Figure 6A). Evidence for caspase-
cleaved APP was evident under the same 
conditions following application of APPccp 
(gray labeling, Figure 6A).  In contrast, while 
there was strong intracellular labeling with Aβ 
1560, there was little evidence for caspase-
cleaved APP in 3xTg-AD mice overexpressing 
Bcl-2 (Figure 6B).  These results suggest that 
overexpression of Bcl-2 prevents the caspase-
cleavage of APP as well as the extracellular 
deposition of Aβ in 3xTg-AD mice.  
 
Experiments were also performed to test 
whether APPccp co-localized with an antibody 
to caspase-cleaved tau (TauC3) developed by 
Gamblin et al [4].  Double-label immunohisto-
Figure 4.  Evidence for the caspase-cleavage of 
APP in 3xTg-AD mice, which is prevented following 
overexpression of Bcl-2.  Immuno-histochemical 
analysis following application of APPccp antibody 
in hippocampal sections from 18 month-old 3xTg-
AD mice (A) or 24 month-old 3xTg-AD mice (C) 
revealed neuronal staining within the subiculum.  
In contrast, in age-matched 3xTg-AD mice 
overexpressing Bcl-2 there was no evidence for 
APPccp staining (B and D).  Data are 
representative staining of a total of n = 3 mice 
from each age group.  All scale bars represent 10 
µm. 
 
Figure 5. Confirmation of the caspase-cleavage of 
APP and its prevention following overexpression of 
Bcl-2 utilizing APPneo.  Application of APPneo, an 
identical site-directed caspase-cleavage antibody 
to APPccp developed by Galvan et al., [6], 
indicated labeling in 3xTg-AD mice that was 
prevented following overexpression of Bcl-2.  (A 
and B): Representative hippocampal staining in 
CA3 region of a 18 month-old 3xTg-AD mice with 
APPneo indicated strong labeling within neuronal 
cell bodies and dystrophic neurites (A) that was 
absent in 3xTg-AD/Bcl-2 OE mice (B).  (C and D): 
Similar results were observed in the cortex of 24 
month-old 3xTg-AD mice (C) and 3xTg-AD/Bcl-2 OE 
mice (D).  All scale bars represent 10 µm.  
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chemical analysis with APPccp and TauC3 
demonstrated co-localization of the two 
antibodies within the subiculum of 24 month-
old 3xTg-AD mice (Figure 6C). In 3xTg-AD/Bcl-2 
OE mice, a reduction in the labeling of both 
antibodies was observed indicating over-
expression of Bcl-2 prevents caspase 
activation and subsequent cleavage of target 
proteins in 3xTg-AD mice (Figure 6D). 
 
Discussion 
 
The amyloid precursor protein (APP) is a 
substrate for caspase-3 mediated cleavage, 
which may contribute to Aβ formation, synaptic 
loss, and the behavioral changes associated 
with AD [6, 11, 18, 19]. The cleavage of APP 
into Aβ represents an early stage in AD, and 
previous research in this regard has focused 
on secretase involvement (α, β and γ) [20].  
Whether or not other proteases contribute to 
the processing of APP is unknown, however, 
studies have suggested that caspase-
mediated cleavage of APP may contribute to 
Aβ formation and lead to the generation of a 
cytotoxic C-terminal peptide termed C31 [21-
23].  We recently demonstrated an 
accumulation of intracellular APP and a lack of 
extracellular plaque formation in 3xTg-AD mice 
following the overexpression of Bcl-2 [8]. Bcl-2 
constitutes a critical control point in apoptosis 
residing immediately upstream of irreversible 
cellular damage, where it prevents the release 
of apoptogenic factors from the mitochondria 
[24].  One interpretation of these results 
showing an accumulation of APP in 3xTg-
AD/Bcl-2 OE mice is that caspases play a role 
in the turnover of this protein.  Blocking 
caspase activation by overexpressing Bcl-2 
prevents cleavage and turnover of APP 
allowing it to accumulate intracellularly within 
neurons.  However, direct evidence for the 
caspase-cleavage of APP and its prevention 
following overexpression of Bcl-2 was not 
demonstrated [8].  The goal of the present 
study was to examine this question directly by 
utilizing a site-directed antibody to caspase-
cleaved APP based on a previous study by 
Gervais et al. [11].  
  
Following the experimental procedures set-
forth in this study, we synthesized an antibody 
to the predicted upstream fragment that would 
be generated following cleavage of full length 
APP by caspase-3 at this site.  To test the 
specificity of our antibody we utilized a cell-
free system consisting of purified human 
recombinant APP incubated with and without 
recombinant caspase-3.  Western blot analysis 
indicated that the APPccp antibody recognizes 
only the caspase-cleaved fragment (~25 kDa) 
but does not detect full length APP (~100 
kDa), indicating that the antibody shows a high 
degree of specificity for the cleaved fragment.  
Following further verification of APPccp as a 
specific marker for caspase-cleaved APP in 
situ, we examined whether the antibody could 
detect cleaved APP in 3xTg-mice and whether 
this cleavage could be prevented following 
overexpression of the anti-apoptotic protein, 
Bcl-2.  Utilizing this antibody as well as a 
similar antibody, APPneo, develop by Galvan et 
al. [16], we now provide evidence for the 
caspase-cleavage of APP in 3xTg-AD mice that 
is prevented following overexpression of Bcl-2.  
These results confirm and extend our previous 
findings and suggest that the caspase-
cleavage of APP is a proximal event that may 
regulate the normal turnover of this protein 
and contribute to extracellular deposition of 
Aβ.  The contribution to the formation of Aβ by 
Figure 6. Prevention of extracellular plaque 
formation and the caspase cleavage of APP and tau 
in 3xTg-AD mice overexpressing Bcl-2.  (A and B): 
Double-label immunohistochemical analysis in 24 
month-old 3xTg-AD mice utilizing mAB anti-A 1560 
(red label) together with APPccp (blue) indicated a 
lack of extracellular plaque deposition and APPccp 
labeling in 3xTg-AD/Bcl- OE mice (B) compared to 
3xTg-AD mice (A). (C and D):  Double-labeling 
immunohistochemical analysis with APPccp (blue) 
and Tau C3 (red) shows co-localization of the two 
antibodies within the subiculum of 24 month-old 
3xTg-AD mice (C). In 3x-Tg-AD/Bcl-2 OE mice, a 
reduction in the labeling of both antibodies was 
observed (D). Data are representative staining from 
n = 3 animals.  All scale bars represent 10 µm. 
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caspases is predicted to occur by two different 
mechanisms.  One, is a through a direct 
interaction of caspase-3 with the C-terminal 
region of APP, leading to proteolytic processing 
of APP [11]. Gervais et al., demonstrated that 
cleavage of APP by caspase-3 enhanced Aβ 
production five-fold [11].  Alternatively, 
caspases may contribute to the formation of 
Aβ, indirectly through cleavage of the beta-site 
APP cleaving enzyme (BACE) trafficking 
protein, GGA3. In a study by Tesco and 
colleagues, caspase activation led to the 
cleavage and stabilization of the BACE 
trafficking molecule, GGA3.  GGA3 plays a role 
in sorting BACE to lysosomes allowing for 
turnover of the enzyme.  Consequently, after 
caspase-3 activation and cleavage of GGA3, 
there is increased availability of BACE leading 
to enhanced production of Aβ [25].  Taken 
together, our findings along with previous 
studies, suggest that caspase activation may 
be an early and important event associated 
with the pathological mechanisms underlying 
AD.  Therefore, therapeutics aimed at 
inhibiting members of the caspase family may 
provide a means of treating AD. 
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